Table 3. MDR phenotype according to patient and tumor characteristics.

	MDR1		MRP		GSTp
Age (year) a
⩽55	5.86±1.12	0.288	83.79±7.77	0.745	70.3±16.91	0.459
>55	4.18±0.95		63.82±6.38		80.1±11.22
Postmenopausal
Yes	3.97±0.75	0.09	70.96±7.85	0.976	81.3±9.44	0.222
No	6.59±1.42		81.78±18.15		65.18±8.44
Clinical T stage
T1	4.95±1.04	0.534	104.21±17.93	0.029	77.1±9.92	0.362
T2	4.83±1.09		54.74±6.1		69.51±7.19
T3	11.2±9.49		35.53±15.57		123.8±84.76
T4	7.25±5.1		43.5±18.28		49.5±20.41
Histologic type b
Ductal carcinomas	5.61±0.93	0.289	81.82±10.68	0.284	73.04±6.9	0.524
Lobular carcinomas	3.32±1.38		53.08±11.93		85.31±22.6
SBR grade c
SBRI	5.13±2.16	0.804	71.83±13.7	0.933	89.63±21.75	0.622
SBRII	4.74±0.96		82.37±19.41		66.4±8.86
SBRIII	5.87±1.42		70.02±7.82		76.83±9.31
Histologic nodal status
N−	6.18±1.58	0.326	79.67±19.59	0.465	85.15±10.0	0.230
N+	4.59±0.8		72.04±7.54		68.91±8.56
Intravascular embolism
Yes	5.28±1.39	0.684	73.66±11.83	0.963	57.07±10.68	0.08
No	4.63±0.87		75.16±12.53		82.7±8.4
Associated extensive in situ carcinoma
Yes	6.04±1.58	0.56	77.04±12.9	0.56	71.32±13.25	0.7
No	4.98±0.91		74.84±11.31		77.33±7.71
Oestrogen receptor status
Negative	7.45±2.04	0.08	60.67±5.16		99.09±12.3
Positive	4.29±0.78		79.31±12.56	0.59	65.39±8.05	0.028
Progesterone receptor status
Negative	5.51±1.52	0.835	67.99±8.29	0.571	87.04±8.7	0.038
Positive	5.15±0.95		79.43±16.72		59.99±9.47
DNA ploidy
Diploid	5.45±1.57	0.735	69.63±10.44	0.164	68.19±11.26	0.298
Aneuploid	6.10±1.15		61.51±5.85		84.31±9.84
S-phase fraction
Low	5.1±1.43	0.312	75.66±11.11	0.580	84.32±15.63	0.719
Medium	4.52±1.59		71.79±13.61		81.72±13.68
High	7.95±1.96		61.29±6.4		70.8±7.4

^aPatient's age.

^bOther histologic types were excluded.

^cSBR: Scarff–Bloom–Richardson index.

Values are expressed as mean±s.e. of RNA levels of MDR1, MRP1 and GSTP1 rt–PCR products, expressed as a percentage of control cell lines. One-way analysis of variance was used to compare these variables.